| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:CDDO-3-P-Im
CAS:1883650-95-0
Purity:98% Remarks:Reach out to us for more information about custom solutions.
|
- CDDO-3P-Im
-
- $88.00 / 1mg
-
2025-11-10
- CAS:1883650-95-0
- Min. Order:
- Purity: 97.72%
- Supply Ability: 10g
- CDDO-3P-Im
-
- $88.00 / 1mg
-
2025-11-10
- CAS:1883650-95-0
- Min. Order:
- Purity: 97.72%
- Supply Ability: 10g
|
| | CDDO-2-P-Im Basic information |
| Product Name: | CDDO-2-P-Im | | Synonyms: | Oleana-1,9(11)-diene-2-carbonitrile, 3,12,28-trioxo-28-[4-(3-pyridinyl)-1H-imidazol-1-yl]-;CDDO-3P-Imidazolide;CPDB1589;CPD1589;CDDO-2-P-Im;CDDO 3P Im,CDDO3PIm;CDDO-3P-Im, 10 mM in DMSO | | CAS: | 1883650-95-0 | | MF: | C39H46N4O3 | | MW: | 618.81 | | EINECS: | | | Product Categories: | | | Mol File: | 1883650-95-0.mol |  |
| | CDDO-2-P-Im Chemical Properties |
| Boiling point | 771.1±70.0 °C(Predicted) | | density | 1.25±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 250 mg/mL (404.00 mM) | | form | Solid | | pka | 3.34±0.12(Predicted) | | color | White to off-white |
| | CDDO-2-P-Im Usage And Synthesis |
| Uses | CDDO-3P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-3P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model[1]. CDDO-3P-Im is a orally active necroptosis inhibitor that can be used for the research of ischemia/reperfusion (I/R)[2]. | | in vivo | CDDO-3P-Im is more stable than CDDO-Im in pharmacokinetic studies[1].
CDDO-3P-Im significantly elevates heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo[1].
CDDO-3P-Im (50-200 mg/kg; diet; for 16 weeks) decreases the number, the size and the severity of tumors in A/J mice[1].
| Animal Model: | Seven week-old female A/J mice[1] | | Dosage: | 50 mg/kg, 200 mg/kg | | Administration: | Diet; for 16 weeks | | Result: | Decreased the number, the size and the severity of tumors. |
| | References | [1] Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47. DOI:10.1016/j.phrs.2015.07.024
[2] Yuanyuan Wang, et al. Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2020 Nov 21;113030. DOI:10.1016/j.ejmech.2020.113030 |
| | CDDO-2-P-Im Preparation Products And Raw materials |
|